about
Managing atrial fibrillation in the very elderly patient: challenges and solutionsAtrial fibrillation in heart failure: what should we do?The role of dronedarone in the treatment of atrial fibrillation/flutter in the aftermath of PALLASAtrial fibrillation therapy now and in the future: drugs, biologicals, and ablationMechanisms of ranolazine's dual protection against atrial and ventricular fibrillationDronedarone-current status in management of atrial fibrillationAn individual patient-based meta-analysis of the effects of dronedarone in patients with atrial fibrillation2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.The current approach of atrial fibrillation management2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of theManagement Of Atrial Fibrillation In Patients With Heart FailureWho Needs Pharmacologic Therapy?2014 AATS guidelines for the prevention and management of perioperative atrial fibrillation and flutter for thoracic surgical procedures.Personalized management of atrial fibrillation: Proceedings from the fourth Atrial Fibrillation competence NETwork/European Heart Rhythm Association consensus conference.Atrial fibrillation: state of the art.Current and emerging antiarrhythmic drug therapy for ventricular tachycardiaUse of antiarrhythmic drug therapy and clinical outcomes in older patients with concomitant atrial fibrillation and coronary artery disease.Rate versus rhythm control in atrial fibrillation.Thyroid and the heartA practical guide for the treatment of symptomatic heart failure with reduced ejection fraction (HFrEF).Costs and clinical consequences of suboptimal atrial fibrillation management.Prolongation of QTc and risk of stroke: The REGARDS (REasons for Geographic and Racial Differences in Stroke) study.How does Chronic Atrial Fibrillation Influence Mortality in the Modern Treatment Era?Addressing the management of atrial fibrillation - a systematic review of the role of dronedarone.Current issues in atrial fibrillation.The use of dronedarone for recurrent ventricular tachycardia: a case report and review of the literature.FDA Policy and Cardiovascular Medicine.ROCKET AF adds more concerns about Digoxin safety in patients with atrial fibrillationProarrhythmic potential of dronedarone: emerging evidence from spontaneous adverse event reportingNovel anti-arrhythmic medications in the treatment of atrial fibrillationCost of atrial fibrillation: invasive vs non-invasive management in 2012Current Evidence and Recommendations for Rate Control in Atrial Fibrillation.The Use of Gene Therapy for Ablation of Atrial Fibrillation.Recent Atrial Fibrillation Guidelines - Looking at Both Sides of the Atlantic.Cost-effectiveness of dronedarone and standard of care compared with standard of care alone: US results of an ATHENA lifetime model.Impact of controlling atrial fibrillation on outcomes relevant to the patient: focus on dronedaroneThe value of basic research insights into atrial fibrillation mechanisms as a guide to therapeutic innovation: a critical analysisN-3 polyunsaturated fatty acids to prevent atrial fibrillation: updated systematic review and meta-analysis of randomized controlled trials.Dronedarone-associated acute renal failure: evidence coming from the Italian spontaneous ADR reporting databaseDysfunction of the thyroid gland during amiodarone therapy: a study of 297 cases
P2860
Q26775877-BE33C628-831B-4435-B691-CEEC6E0A6870Q26784426-801AA662-9A68-469C-B57E-0E6FFA071E87Q26853369-08FF106D-6ED7-4AEA-A7F1-9B9E30E8953FQ26864767-262564A7-22E8-4BB6-9FD9-7DA5E356008AQ26995558-56365CD1-04AF-41CE-9389-2985E88DBBCCQ27001666-6F5102CC-4AA6-4659-8815-06434EA9C033Q27011828-63647FA3-E89D-47FA-BF80-ADF45EC1FE14Q27341873-963C05C6-7A07-4A06-8F98-325E7B719AF2Q28076171-7B43DCCC-B96D-4155-89D9-EC7823B1F004Q28087002-4186505E-A2C0-47BE-8FDF-DF6DC1CD3E66Q30354835-03133C5A-E5F7-4C27-A0D6-B128407CDEC6Q30354838-B1D04A35-7C37-4D49-8FAD-CD8321631D3EQ30653045-6884DCEB-D4DE-4EFE-9231-32F1C11C1941Q30663685-D3D09A37-0B75-4C4E-ADCA-CECA2F9B00E9Q33359459-D1B4CA9A-DE4B-41E0-98C7-B25D709C878EQ33936131-E8810D7B-E323-4074-8718-F8873C67ED92Q34169705-55FB9895-7E99-4321-B9E0-1BE6557FA8C6Q34328299-EB676F28-63B6-4730-AC00-F5BD2CFADB00Q35054125-89B8579A-45C6-4824-A985-EC50EDBC9175Q35139947-B58CA095-4E33-4606-A2B0-5BD15995CCE4Q35885128-93F9FBCC-786F-4E6B-928E-A1C076AAE8BEQ35936585-B3609AEE-FD77-408C-86A0-517AFB0A0C4CQ36021753-4E30BB1F-2448-4BD3-9012-59D8C406934CQ36026806-11BEDB2B-361F-4947-839D-BA2A5379F623Q36072140-30355300-D496-4BF7-AAFD-54094A019E6AQ36086657-B15711AF-C026-4FD4-AD06-A48814C1DA41Q36100416-89877AC1-0F18-47C3-836A-BE055B8824EDQ36249617-756AC743-9FA4-4D59-8283-791F48AE16E7Q36295826-44951579-0ADB-4C96-8D78-9BC7CE776E48Q36382379-793BECCB-5025-426B-B18A-670553C8BCC7Q36382393-05C214BD-B201-4851-BEDF-1754FDD1A506Q36458858-89A5E109-60DA-4A9C-9B4F-7D615DDB12CFQ36458906-AAAB6C72-D632-457D-B8CD-C57D1188F436Q36461724-1D2AA77B-48ED-4B2B-AAE6-6998EDDE6786Q36530069-5596C400-6795-4335-94C6-7AB7EBAF0315Q36569905-2D79E253-71E4-46AD-9275-F1763CB44633Q36650575-13984DD1-3867-4129-9559-6A1DA688D7B5Q36701732-37B7ABD7-5E06-4ED5-80FB-DE34ADAB6A09Q36793003-CBE912AC-19CD-4EF9-94C1-3B6178CFDEEDQ36798000-2382A6F8-CF68-46BA-9D55-A97F655BC19A
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Dronedarone in High-Risk Permanent Atrial Fibrillation
@ast
Dronedarone in High-Risk Permanent Atrial Fibrillation
@en
type
label
Dronedarone in High-Risk Permanent Atrial Fibrillation
@ast
Dronedarone in High-Risk Permanent Atrial Fibrillation
@en
prefLabel
Dronedarone in High-Risk Permanent Atrial Fibrillation
@ast
Dronedarone in High-Risk Permanent Atrial Fibrillation
@en
P2093
P50
P3181
P356
P1476
Dronedarone in High-Risk Permanent Atrial Fibrillation
@en
P2093
A. John Camm
Alexander Parkhomenko
Andrzej Budaj
Antonio Dans
Antonio Gonzalez-Hermosillo
Basil S. Lewis
Calambur Narasimhan
Campbell Joyner
Carlos Morillo
Chi Keong Ching
P304
P3181
P356
10.1056/NEJMOA1109867
P407
P50
P577
2011-12-15T00:00:00Z